1396777-41-5

Basic information

• Product Name: 8-bromo-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one
• Synonyms: 8-bromo-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one
• CAS NO: 1396777-41-5
• Molecular Weight: 242.072
• Mol File: 1396777-41-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 8-bromo-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8-bromo-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one(1396777-41-5)
• EPA Substance Registry System: 8-bromo-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one(1396777-41-5)

Safety Data

• Hazardous Substances Data: 1396777-41-5(Hazardous Substances Data)

Upstream product

• 22717-56-2 4-bromo-2-Hydroxybenzoic Acid Methylester 
• 49660-57-3 6-bromochroman-4-one 
• 18442-22-3 7-Bromo-2,3-dihydro-4H-chromen-4-one 
• 27407-19-8 7-bromochroman-4-one oxime 

Downstream Products

• 1215074-47-7 8-bromo-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine 

Relevant articles and documents

Discovery of 3,4-Dihydrobenzo[ f][1,4]oxazepin-5(2 H)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects

The Traf2- and Nck-interacting protein kinase (TNIK) is a downstream signal protein of the Wnt/β-catenin pathway and has been thought of as a potential target for the treatment of colorectal cancer (CRC) that is often associated with dysregulation of Wnt/

PYRROLO[2,3-B]PYRIDINES AS HPK1 INHIBITOR AND USES THEREOF

Disclosed herein is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

ALDOSTERONE SYNTHASE INHIBITORS

The present invention relates to compounds of the formulas (IA) and (IB) and pharmaceutically acceptable salts thereof, wherein A and R1 - R6, are as defined herein. The invention also relates to pharmaceutical compositions comprisin